<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ERTAPENEM SODIUM</span><br/>(er-ta-pen'em)<br/><span class="topboxtradename">Invanz<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">beta-lactam antibiotic</span><br/><b>Prototype: </b>Imipenem-Cilastatin<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 g vial</p>
<h1><a name="action">Actions</a></h1>
<p>Broad-spectrum carbapenem antibiotic that inhibits the cell wall synthesis of gram-positive and gram-negative bacteria by
         its strong affinity for penicillin-binding proteins (PBPs) of the bacterial cell wall.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against both gram-positive and gram-negative bacteria. Highly resistant to most bacterial beta-lactamases. Effective
         against most <i>Enterobacteriaceae, Pseudomonas aeruginosa</i>, and <i>Acinetobacter</i> spp. It is poorly effective against <i>Enterococci</i> bacteria, particularly vancomycin-resistant strains (VRSA).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Complicated intraabdominal infections, complicated skin and skin structure infections, community-acquired pneumonia, complicated
         UTI (including pyelonephritis), and acute pelvic infections due to susceptible bacteria.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ertapenem; hypersensitivity to amide-type local anesthetics such as lidocaine; hypersensitivity to meropenem
         or imipenem; previous anaphylactic reaction to beta-lactams.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment; history of CNS disorders; history of seizures; hypersensitivity to other beta-lactam antibiotics (penicillins,
         cephalosporins); pregnancy (category B); hypersensitivity to other allergens; meningitis; lactation (bottle feed during, and
         for 5 d after therapy ends).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Community Acquired Pneumonia; Complicated UTI</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 1 g q.d. <small>x</small> 1014 d May switch to appropriate PO antibiotic after 3 d if responding<br/><br/><span class="indicationtitle">Intraabdominal Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 1 g q.d. <small>x</small> 514 d<br/><br/><span class="indicationtitle">Skin and Skin Structure Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 1 g q.d. <small>x</small> 714 d<br/><br/><span class="indicationtitle">Acute Pelvic Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 1 g q.d. <small>x</small> 310 d<br/><br/><span class="impairmenttitle">Renal Impairment (all indications)</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute 1 g vial with 3.2 mL of 1.0% lidocaine HCI injection (without epinephrine). Shake vial thoroughly to form
            solution. Use immediately.
         </li>
<li>Inject deep IM into a large muscle mass (such as the gluteal muscles or lateral part of the thigh).</li>
<li>The reconstituted IM solution should be used within 1 h after preparation. Note: DO NOT use this solution for IV administration.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Reconstitute 1 g vial with 10 mL of sterile water for injection, NS, or bacteriostatic water for injection. Shake well to
                  dissolve and immediately transfer contents to 50 mL of NS injection solution.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span> Infuse over 30 min. Note: Infusion should be completed within 6 h of reconstitution.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<b>Dextrose.</b>
<span class="incompattype">Y-site:</span> Do not mix or infuse with any other drugs. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store lyophilized powder above 25° C (77° F). May store reconstituted solution for 6 h at room temperature (not
            greater than 25° C/77° F) or for 24 h under refrigeration. Use within 4 h of removal from refrigeration. Do not
            freeze.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Phlebitis or thrombosis at injection site, asthenia, fatigue, <span class="speceff-life">death</span>, fever, leg pain. <span class="typehead">CNS:</span> Anxiety, altered mental status, dizziness, headache, insomnia. <span class="typehead">CV:</span> Chest pain, hypertension, hypotension, tachycardia, edema. <span class="typehead">GI:</span> Abdominal pain, <span class="speceff-common">diarrhea</span>, acid regurgitation, constipation, dyspepsia, nausea, vomiting, increased AST and ALT. <span class="typehead">Respiratory:</span> Cough, dyspnea, pharyngitis, rales/rhonchi, and respiratory distress. <span class="typehead">Skin:</span> Erythema, pruritus, rash. <span class="typehead">Urogenital:</span> Vaginitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Probenecid</b> decreases renal excretion. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 90% absorbed from IM site. <span class="typehead">Peak:</span> 2.3 h. <span class="typehead">Distribution:</span> 95% protein bound, distributes into breast milk, may cross placenta. <span class="typehead">Metabolism:</span> Hydrolysis of beta-lactam ring. <span class="typehead">Elimination:</span> 80% excreted in urine, 10% in feces. <span class="typehead">Half-Life:</span> 4.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Perform C&amp;S tests prior to therapy. Monitor periodically liver and kidney function.</li>
<li>Determine history of hypersensitivity reactions to other beta-lactams, cephalosporins, penicillins, or other drugs.</li>
<li>Discontinue drug and immediately report S&amp;S of hypersensitivity (see Appendix F).</li>
<li>Report S&amp;S of superinfection or pseudomembranous colitis (see Appendix F).</li>
<li>Monitor for seizures especially in older adults and those with renal insufficiency.</li>
<li>Lab tests: Monitor AST, ALT, alkaline phosphatase, CBC, platelet count, and routine blood chemistry during prolonged therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn S&amp;S of hypersensitivity, superinfection, and pseudomembranous colitis (see Appendix F); report any of these to physician
            promptly.
         </li>
<li>Do not breast feed during and for at least 5 d following termination of therapy.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>